If a patient has severe asthma or did not benefit from ICS medications, further treatments including biological agents which act on IL-5 (mepolizumab, reslizumab), IL-4/IL-13 (dupilumab) or IgE (omalizumab) can be used. This evidence concerns the gene IL13 and asthma.